DKN-01 plus tislelizumab and chemotherapy demonstrated compelling activity in first-line patients with gastric or gastroesophageal junction cancer
- In patients who received a full cycle of DKN-01 therapy, the ORR was 68.2%, with 90% ORR in patients with DKK1-high tumors
- Further results will be presented at the ESMO 2021 Congress from September 16 to 21, 2021
- Company to host conference call on Friday, September 17, 2021 at 8:00 a.m. ET
Conference Call
Leap will host a conference call on Friday, September 17, 2021 at 8:00 a.m. Eastern Time to further discuss the data. In addition to Leap's executive management team, Dr Jaffer Ajani of M.D. Anderson Cancer Center and Dr. Samuel Klempner of Massachusetts General Hospital will be on the call. The call can be accessed by dialing (866) 589-0108 (U.S. and Canada) or (409) 231-2048 (international). The passcode for the conference call is 1729397. The presentation will be webcast live and may be accessed on the Investors page of the Company's website at https://investors.leaptx.com/, where a replay of the event will also be available for a limited time.
https://finance.yahoo.com/news/leap-therapeutics-present-data-distinguish-100000549.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.